Eli Lilly reports positive Phase 3 results for orforglipron in type 2 diabetes trials
Eli Lilly highlights findings from two late-stage trials demonstrating orforglipron’s effectiveness in improving blood sugar…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
type 2 diabetes
Lilly launches Mounjaro KwikPen (tirzepatide) in India
The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing healthcare…
Morepen Laboratories receives CDSCO clearance for bioequivalence studies on Resmetirom
Morepen Laboratories advances Resmetirom development for NASH treatment following SEC approval
Akums launches Dapagliflozin + Pioglitazone tablets for type 2 diabetes
New dual-action therapy targets insulin resistance and glycaemic control
Dr Reddy’s Glycemic Happiness Awareness initiative sets Guinness World Record
Dr Reddy's collaborated with endocrinologists and diabetologists on the concept of 'glycemic happiness' for patients living with…
GLP-1R market: A two-horse race, says GlobalData
As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase…
Ozempic linked with lower dementia risk, nicotine use, British study finds
The study, published in the Lancet's eClinicalMedicine journal, explored more than 100 million medical records of the U.S.…
Innovent Biologics mazdutide can pave way for transformative T2D treatment: GlobalData
Mazdutide will be the second drug from Innovent Biologics in Chinese metabolic disorders market
GLP-1R agonists’ type 2 diabetes and obesity market to reach $125 billion in 7MM by 2033: GlobalData
According to GlobalData, more than 190 million people currently live with type 2 diabetes and/or obesity in 7MM, and the numbers…
GLP-1R agonists clinical trial design needs to be improved to reassure drugs’ benefits: GlobalData
According to GlobalData, there are over 50 clinical trials for type 2 diabetes or obesity treatment involving GLP-1R agonists